Drug
Bictegravir Lenacapavir Fdc
Bictegravir Lenacapavir Fdc: highest development phase Phase 3, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bictegravir/Lenacapavir (BIC/LEN) FDC NCT06333808 | Phase 3 | HIV-1-infection |
Latest
No recent events.
Follow Bictegravir Lenacapavir Fdc on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.